- Karen Colonias to step down as CEO on December 31, 2022, and retire from the Company on June 30, 2023
- Michael Olosky to succeed Karen Colonias as Chief Executive Officer on January 1, 2023
Syndax Late Tuesday Announced it Priced ~6.8M Public Share Offering of Common Stock @$22/Share
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the pricing of an underwritten public offering of 6,818,182 shares of its common stock.
